Chemical Synthesis and Characterisation of the Complement C5 Inhibitory Peptide Zilucoplan

Overview

Journal Amino Acids

Specialty Biochemistry

Date 2021 Jan 5

PMID 33398524

Citations 4

Authors

Declan M Gorman

John Lee

Colton D Payne

Trent M Woodruff

Richard J Clark

Affiliations

Soon will be listed here.

Abstract

The complement component C5 inhibitory peptide zilucoplan is currently in phase III clinical trials for myasthenia gravis (MG). Despite being at an advanced stage of clinical development, there have been no published reports in the literature detailing its chemical synthesis. In this work, we describe an approach for the chemical synthesis of zilucoplan and validate that the synthesised compound blocks LPS-induced C5a production from human blood.

Citing Articles

Praziquantel and factor H recruitment differentially affect the susceptibility of to complement-mediated damage.

van Beek A, Jeanguenat H, Haberli C, Pouw R, Lamers C, Pal G Front Immunol. 2024; 15:1474358.

PMID: 39600706 PMC: 11588701. DOI: 10.3389/fimmu.2024.1474358.

Tipping the balance: intricate roles of the complement system in disease and therapy.

Pouw R, Ricklin D Semin Immunopathol. 2021; 43(6):757-771.

PMID: 34698894 PMC: 8547127. DOI: 10.1007/s00281-021-00892-7.

Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives.

Cabri W, Cantelmi P, Corbisiero D, Fantoni T, Ferrazzano L, Martelli G Front Mol Biosci. 2021; 8:697586.

PMID: 34195230 PMC: 8236712. DOI: 10.3389/fmolb.2021.697586.

Directing evolution of novel ligands by mRNA display.

Kamalinia G, Grindel B, Takahashi T, Millward S, Roberts R Chem Soc Rev. 2021; 50(16):9055-9103.

PMID: 34165126 PMC: 8725378. DOI: 10.1039/d1cs00160d.

References

Beecher G, Putko B, Wagner A, Siddiqi Z . Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status. Drugs. 2019; 79(4):353-364. DOI: 10.1007/s40265-019-1065-0. View

Brodsky R, Young N, Antonioli E, Risitano A, Schrezenmeier H, Schubert J . Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 111(4):1840-7. DOI: 10.1182/blood-2007-06-094136. View

Carvelli J, Demaria O, Vely F, Batista L, Chouaki Benmansour N, Fares J . Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis. Nature. 2020; 588(7836):146-150. PMC: 7116884. DOI: 10.1038/s41586-020-2600-6. View

Cofiell R, Kukreja A, Bedard K, Yan Y, Mickle A, Ogawa M . Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS. Blood. 2015; 125(21):3253-62. PMC: 4449039. DOI: 10.1182/blood-2014-09-600411. View

Denk S, Taylor R, Wiegner R, Cook E, Lindorfer M, Pfeiffer K . Complement C5a-Induced Changes in Neutrophil Morphology During Inflammation. Scand J Immunol. 2017; 86(3):143-155. PMC: 5773343. DOI: 10.1111/sji.12580. View

Howard Jr J, Utsugisawa K, Benatar M, Murai H, Barohn R, Illa I . Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017; 16(12):976-986. DOI: 10.1016/S1474-4422(17)30369-1. View

Freimer M, Vu T, Benatar M, MacDougall J, Barohn R, Dimachkie M . Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial. JAMA Neurol. 2020; 77(5):582-592. PMC: 7042797. DOI: 10.1001/jamaneurol.2019.5125. View

Jayne D, Bruchfeld A, Harper L, Schaier M, Venning M, Hamilton P . Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol. 2017; 28(9):2756-2767. PMC: 5576933. DOI: 10.1681/ASN.2016111179. View

Legendre C, Licht C, Muus P, Greenbaum L, Babu S, Bedrosian C . Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23):2169-81. DOI: 10.1056/NEJMoa1208981. View

10.

Lo M, Kemper C, Woodruff T . COVID-19: Complement, Coagulation, and Collateral Damage. J Immunol. 2020; 205(6):1488-1495. PMC: 7484432. DOI: 10.4049/jimmunol.2000644. View

11.

Pandey S, Maharana J, Li X, Woodruff T, Shukla A . Emerging Insights into the Structure and Function of Complement C5a Receptors. Trends Biochem Sci. 2020; 45(8):693-705. DOI: 10.1016/j.tibs.2020.04.004. View

12.

Pittock S, Lennon V, McKeon A, Mandrekar J, Weinshenker B, Lucchinetti C . Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol. 2013; 12(6):554-62. DOI: 10.1016/S1474-4422(13)70076-0. View

13.

Scholz W, McClurg M, Cardenas G, Smith M, Noonan D, Hugli T . C5a-mediated release of interleukin 6 by human monocytes. Clin Immunol Immunopathol. 1990; 57(2):297-307. DOI: 10.1016/0090-1229(90)90043-p. View

14.

Wishart D, Bigam C, Holm A, Hodges R, Sykes B . 1H, 13C and 15N random coil NMR chemical shifts of the common amino acids. I. Investigations of nearest-neighbor effects. J Biomol NMR. 1995; 5(1):67-81. DOI: 10.1007/BF00227471. View

15.

Woodruff T, Shukla A . The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics. Trends Immunol. 2020; 41(11):965-967. PMC: 7510552. DOI: 10.1016/j.it.2020.09.008. View

16.

Woodruff T, Pollitt S, Proctor L, Stocks S, Manthey H, Williams H . Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther. 2005; 314(2):811-7. DOI: 10.1124/jpet.105.086835. View

17.

Yee A, Oleskie A, Dosey A, Kretz C, Gildersleeve R, Dutta S . Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII. Blood. 2015; 126(8):939-42. PMC: 4543228. DOI: 10.1182/blood-2015-04-641696. View

18.

Zhang J, Payne C, Pouvreau B, Schaefer H, Fisher M, Taylor N . An Ancient Peptide Family Buried within Vicilin Precursors. ACS Chem Biol. 2019; 14(5):979-993. DOI: 10.1021/acschembio.9b00167. View